• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

连续多点干预的因果推断。

Causal Inference for Continuous Multiple Time Point Interventions.

机构信息

Department of Statistics, Ludwig-Maximilians University, Munich, Germany.

Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.

出版信息

Stat Med. 2024 Dec 10;43(28):5380-5400. doi: 10.1002/sim.10246. Epub 2024 Oct 17.

DOI:10.1002/sim.10246
PMID:39420673
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11586917/
Abstract

There are limited options to estimate the treatment effects of variables which are continuous and measured at multiple time points, particularly if the true dose-response curve should be estimated as closely as possible. However, these situations may be of relevance: in pharmacology, one may be interested in how outcomes of people living with-and treated for-HIV, such as viral failure, would vary for time-varying interventions such as different drug concentration trajectories. A challenge for doing causal inference with continuous interventions is that the positivity assumption is typically violated. To address positivity violations, we develop projection functions, which reweigh and redefine the estimand of interest based on functions of the conditional support for the respective interventions. With these functions, we obtain the desired dose-response curve in areas of enough support, and otherwise a meaningful estimand that does not require the positivity assumption. We develop -computation type plug-in estimators for this case. Those are contrasted with g-computation estimators which are applied to continuous interventions without specifically addressing positivity violations, which we propose to be presented with diagnostics. The ideas are illustrated with longitudinal data from HIV positive children treated with an efavirenz-based regimen as part of the CHAPAS-3 trial, which enrolled children years in Zambia/Uganda. Simulations show in which situations a standard g-computation approach is appropriate, and in which it leads to bias and how the proposed weighted estimation approach then recovers the alternative estimand of interest.

摘要

对于那些需要尽可能精确地估计真实剂量-反应曲线的连续且在多个时间点测量的变量,其治疗效果的估计方法有限。然而,以下情况可能具有相关性:在药理学中,人们可能会关注患有 HIV 并接受治疗的人群(如病毒失败)的结果会如何随时间变化的干预措施(如不同的药物浓度轨迹)而变化。对于连续干预措施进行因果推断的一个挑战是,正性假设通常会被违反。为了解决正性违反问题,我们开发了投影函数,这些函数基于各自干预措施的条件支持的函数,对感兴趣的估计量进行重新加权和重新定义。通过这些函数,我们在有足够支持的区域中获得所需的剂量-反应曲线,否则,获得一个不需要正性假设的有意义的估计量。我们为此开发了 -计算类型的插补估计量。与 g 计算估计量形成对比,后者应用于没有专门解决正性违反问题的连续干预措施,我们建议对此类估计量使用诊断工具。这些想法通过来自 HIV 阳性儿童的纵向数据进行说明,这些儿童在赞比亚/乌干达接受基于依非韦仑的方案治疗,是 CHAPAS-3 试验的一部分。模拟结果表明,在哪些情况下标准的 g 计算方法是合适的,以及在哪些情况下会导致偏差,以及拟议的加权估计方法如何恢复替代的感兴趣的估计量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/00d7f9384bf6/SIM-43-5380-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/b6c51a05b36a/SIM-43-5380-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/ef297a49bed3/SIM-43-5380-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/ceb28c555865/SIM-43-5380-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/a3e0e53dbb09/SIM-43-5380-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/e51568ccbc41/SIM-43-5380-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/00d7f9384bf6/SIM-43-5380-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/b6c51a05b36a/SIM-43-5380-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/ef297a49bed3/SIM-43-5380-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/ceb28c555865/SIM-43-5380-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/a3e0e53dbb09/SIM-43-5380-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/e51568ccbc41/SIM-43-5380-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ddf1/11586917/00d7f9384bf6/SIM-43-5380-g006.jpg

相似文献

1
Causal Inference for Continuous Multiple Time Point Interventions.连续多点干预的因果推断。
Stat Med. 2024 Dec 10;43(28):5380-5400. doi: 10.1002/sim.10246. Epub 2024 Oct 17.
2
Determining Targets for Antiretroviral Drug Concentrations: A Causal Framework Illustrated With Pediatric Efavirenz Data From the CHAPAS-3 Trial.确定抗逆转录病毒药物浓度的目标:一个因果框架,以CHAPAS-3试验中的儿科依非韦伦数据为例说明
Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70051. doi: 10.1002/pds.70051.
3
Recoverability of causal effects under presence of missing data: a longitudinal case study.存在缺失数据时因果效应的可恢复性:一项纵向案例研究。
Biostatistics. 2024 Dec 31;26(1). doi: 10.1093/biostatistics/kxae044.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Double Robust Efficient Estimators of Longitudinal Treatment Effects: Comparative Performance in Simulations and a Case Study.纵向治疗效果的双重稳健有效估计量:模拟中的比较性能及一个案例研究
Int J Biostat. 2019 Feb 26;15(2):/j/ijb.2019.15.issue-2/ijb-2017-0054/ijb-2017-0054.xml. doi: 10.1515/ijb-2017-0054.
6
Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.基于依非韦伦的方案在治疗结核病的年轻 HIV 感染儿童中的效果:资源有限环境下的一种治疗选择。
PLoS One. 2013;8(1):e55111. doi: 10.1371/journal.pone.0055111. Epub 2013 Jan 25.
7
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.标准剂量拉替拉韦或依非韦伦为基础的抗逆转录病毒治疗方案用于 HIV 和结核病合并感染患者(ANRS 12 300 Reflate TB 2):一项开放标签、非劣效性、随机、3 期临床试验。
Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2.
8
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.阿巴卡韦、齐多夫定或司他夫定作为非洲感染艾滋病毒儿童的儿科片剂(CHAPAS-3):一项开放标签、平行组、随机对照试验。
Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.
9
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.BREATHER 研究:基于依非韦伦的周末停药方案治疗 HIV 感染的儿童、青少年和年轻成人:一项随机、开放标签、非劣效性、2/3 期临床试验。
Lancet HIV. 2016 Sep;3(9):e421-e430. doi: 10.1016/S2352-3018(16)30054-6. Epub 2016 Jun 20.
10
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.在病毒抑制的 HIV 阳性患者中,从 coformulated 600-mg efavirenz、tenofovir disoproxil fumarate 和 emtricitabine 转换为 coformulated 400-mg efavirenz、tenofovir disoproxil fumarate 和 lamivudine 的治疗药物监测研究。
J Microbiol Immunol Infect. 2021 Oct;54(5):944-951. doi: 10.1016/j.jmii.2020.06.010. Epub 2020 Jul 7.

引用本文的文献

1
Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.估计暴露因素对事件发生时间结局的因果效应时使用靶向最大似然法和机器学习的指南与最佳实践
Stat Med. 2025 Mar 15;44(6):e70034. doi: 10.1002/sim.70034.
2
Determining Targets for Antiretroviral Drug Concentrations: A Causal Framework Illustrated With Pediatric Efavirenz Data From the CHAPAS-3 Trial.确定抗逆转录病毒药物浓度的目标:一个因果框架,以CHAPAS-3试验中的儿科依非韦伦数据为例说明
Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70051. doi: 10.1002/pds.70051.
3
Recoverability of causal effects under presence of missing data: a longitudinal case study.
存在缺失数据时因果效应的可恢复性:一项纵向案例研究。
Biostatistics. 2024 Dec 31;26(1). doi: 10.1093/biostatistics/kxae044.